A Visual and Narrative Timeline Review of Spinal Cord Stimulation Technology and US Food and Drug Administration Milestones

被引:0
|
作者
Ho, Johnson S. [1 ]
Poon, Cynthia [2 ]
North, Richard [3 ,4 ]
Grubb, William [1 ]
Lempka, Scott [5 ,6 ,7 ]
Bikson, Marom [8 ]
机构
[1] Rutgers Robert Wood Johnson Med Sch, Dept Anesthesiol, 125 Paterson St,CAB 3100, New Brunswick, NJ 08901 USA
[2] Columbia Univ, Dept Biomed Engn, New York, NY USA
[3] Neuromodulat Fdn Inc, Baltimore, MD USA
[4] Johns Hopkins Univ, Dept Neurosurg, Sch Med, Baltimore, MD USA
[5] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI USA
[6] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI USA
[7] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI USA
[8] CUNY City Coll, Dept Biomed Engn, New York, NY USA
来源
NEUROMODULATION | 2024年 / 27卷 / 06期
关键词
Key milestones; narrative timeline; neuromodulation; pain management; review article; spinal cord stimulation; DORSAL COLUMN STIMULATION; EPIDURAL ELECTRICAL-STIMULATION; FINITE-ELEMENT-ANALYSIS; CHRONIC BACK; CHRONIC PAIN; DESIGN; TRIAL; NEUROSTIMULATION; NEUROMODULATION; MULTICHANNEL;
D O I
10.1016/j.neurom.2024.05.006
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: The aim of this study was to present key technologic and regulatory milestones in spinal cord stimulation (SCS) for managing chronic pain on a narrative timeline with visual representation, relying on original sources to the extent possible. Materials and Methods: We identified technical advances in SCS that facilitated and enhanced treatment on the basis of scientific publications and approvals from the United States (US) Food and Drug Administration (FDA). We presented milestones limited to first use in key indications and in the context of new technology validation. We focused primarily on pain management, but other indications (eg, motor disorder in multiple sclerosis) were included when they affected technology development. Results: We developed a comprehensive visual and narrative timeline of SCS technology and US FDA milestones. Since its conception in the 1960s, the science and technology of SCS neuromodulation have continuously evolved. Advances span lead design (from paddle-type to percutaneous, and increased electrode contacts) and stimulator technology (from wireless power to internally powered and rechargeable, with miniaturized components, and programmable multichannel devices), with expanding stimulation program flexibility (such as burst and kilohertz stimulation frequencies), as well as usage features (such as remote programming and magnetic resonance imaging conditional compatibility). Conclusions: This timeline represents the evolution of SCS technology alongside expanding FDA-approved indications for use.
引用
收藏
页码:1020 / 1025
页数:6
相关论文
共 50 条
  • [31] EVOLUTION AT THE US FOOD AND DRUG ADMINISTRATION: SCOPING REVIEW TO ASSESS RISK TOLERANCE OF FDA FOR NEW MEDICAL DEVICES AND TECHNOLOGY IN GASTROENTEROLOGY
    Xue, Shan
    Hennessey, Megan M.
    Strigenz, Rebecca Z.
    Shah, Eric D.
    GASTROENTEROLOGY, 2024, 166 (05) : S1215 - S1215
  • [32] USE OF EXTERNAL CONTROL ARMS IN NOVEL DRUG APPROVALS BY US FOOD AND DRUG ADMINISTRATION: A TARGETED REVIEW
    Gupta, P.
    Kumar, J.
    Shaikh, J.
    VALUE IN HEALTH, 2024, 27 (06) : S204 - S204
  • [33] Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox
    Chan-Tack, Kirk M.
    Harrington, Patrick R.
    Choi, Su-Young
    Myers, Laine
    O'Rear, Julian
    Seo, Shirley
    McMillan, David
    Ghantous, Hanan
    Birnkrant, Debra
    Sherwat, Adam, I
    LANCET INFECTIOUS DISEASES, 2019, 19 (06): : E221 - E224
  • [34] Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury
    Scholpa, Natalie E.
    Williams, Hannah
    Wang, Wenxue
    Corum, Daniel
    Narang, Aarti
    Tomlinson, Stephen
    Sullivan, Patrick G.
    Rabchevsky, Alexander G.
    Schnellmann, Rick G.
    JOURNAL OF NEUROTRAUMA, 2019, 36 (06) : 962 - 972
  • [35] Painful Diabetic Neuropathy-Spinal Cord Stimulation, Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation, and Scrambler Therapy: A Narrative Review
    Wang, Eric J.
    Berninger, Lauren E.
    Komargodski, Olga
    Smith, Thomas J.
    PAIN PHYSICIAN, 2022, 25 (08) : E1161 - +
  • [36] Improving data capture of race and ethnicity for the Food and Drug Administration Sentinel database: a narrative review
    Ter-Minassian, Monica
    Dinucci, Anna J.
    Barrie, Issmatu S.
    Schoeplein, Ryan
    Chakravarty, Aloka
    Hernandez-Munoz, Jose J.
    ANNALS OF EPIDEMIOLOGY, 2023, 86 : 80 - 89.e2
  • [37] The Role of the US Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology
    McKee, Amy E.
    Farrell, Ann T.
    Pazdur, Richard
    Woodcock, Janet
    ONCOLOGIST, 2010, 15 : 13 - 18
  • [38] Role of patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain: a comprehensive narrative review
    Shanthanna, Harsha
    Eldabe, Sam
    Provenzano, David Anthony
    Chang, Yaping
    Adams, Daniel
    Kashir, Imad
    Goel, Akash
    Tian, Chenchen
    Couban, Rachel J.
    Levit, Tal
    Hagedorn, Jonathan M.
    Narouze, Samer
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2023, 48 (06) : 251 - 272
  • [39] US Food and Drug Administration Systematic Review of Pregnancy Registries: Follow-up Analysis
    Sahin, L.
    Hammad, H.
    Bird, S.
    Gelperin, K.
    Hampp, C.
    Leishear, K.
    Taylor, L.
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2015, 103 (05) : 391 - 391
  • [40] US Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program
    de Claro, R. Angelo
    Gao, Jennifer J.
    Kim, Tamy
    Kluetz, Paul G.
    Theoret, Marc R.
    Beaver, Julia A.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 11 - 14